Healthcare DIVE December 12, 2019
Dive Brief:
- CVS Health unveiled a precision medicine program for oncology patients Thursday designed to increase access to broad-panel gene sequencing tests for patients with specific advanced stage cancers.
- The Woonsocket, Rhode Island-based healthcare behemoth is partnering with Tempus, a precision medicine company, to help clinicians develop a personalized regimen for cancer patients to limit disease progression and reduce unnecessary costs.
- Results from the genetic tests will also be used to match eligible patients to clinical trials in their area. CVS-owned payer Aetna has already adopted the program for its fully insured commercial beneficiaries and is rolling it out with participating Aetna provider networks in 12 states.
Dive Insight:
CVS executives have teased an oncology care pilot for...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, Insurance, Payer, Pharma, Precision Medicine, Provider, Retail care, Technology